

209696 - A targeted safety study, EPI-ZOSTER-032 VS US DB, to evaluate the safety of Shingrix in adults \geq 65 years of age in the United States.

First published: 11/09/2020

Last updated: 16/04/2025

Study

Ongoing

Administrative details

EU PAS number

EUPAS37133

Study ID

48959

DARWIN EU® study

No

Study countries

☐ United States

Study description

Targeted safety study to assess the real-world safety of Shingrix vaccine in the US using the Centers for Medicare and Medicaid Services (CMS) Chronic Condition Warehouse (CCW) database with a focus on specific health outcomes of interest in adults aged 65 and older.

Study status

Ongoing

Contact details

Study institution contact

Call Center EU Clinical Trials

Vx.publicdisclosureglobal@gsk.com

Study contact

Vx.publicdisclosureglobal@gsk.com

Primary lead investigator

Call Center EU Clinical Trials

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual: 18/08/2020

Study start date

Planned: 11/09/2020

Actual: 11/09/2020

Date of final study report

Planned: 23/03/2026

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

GlaxoSmithKline

Study protocol

[Redacted EPI-ZOSTER-032 Protocol Amendment 3 Anonymized 16 Aug 2022.pdf](#)
(914.29 KB)

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)

Methodological aspects

Study type

Study type list

Study topic:

Disease /health condition

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness

Safety study (incl. comparative)

Data collection methods:

Secondary use of data

Main study objective:

To assess whether Shingrix, or RZV, is associated with an increased risk of new-onset Guillain-Barré Syndrome (GBS), Gout, Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA), Ischemic Optic Neuropathy (ION) or Supraventricular Tachycardia (SVT) within specified time periods after vaccination in people ≥ 65 years of age beginning January 2018 in CMS Medicare.

Study Design

Non-interventional study design

Cohort

Other

Non-interventional study design, other

Targeted safety study (TSS) and a post-authorization safety study (PASS)

Study drug and medical condition

Name of medicine

SHINGRIX

Study drug International non-proprietary name (INN) or common name

HERPES ZOSTER VACCINE (RECOMBINANT, ADJUVANTED)

Medical condition to be studied

Herpes zoster

Population studied

Short description of the study population

The study population included patients aged 65 years or older who had received at least one dose of Shingrix, recombinant zoster vaccine (RZV) for the treatment of herpes zoster identified from CMS chronic conditions warehouse Medicare database from January 2017 to December 2021.

Inclusion criteria:

US Medicare beneficiaries who meet the following criteria will be included in the study:

1. Age 65 and older at the date of the RZV vaccination or preventive care visit for the RZV unvaccinated comparator
2. Enrolled in Medicare due to age or ESRD as the original and current qualifying reason
3. Continuously enrolled in Medicare Parts A, B, and D fee-for-service for at least 365 days preceding the date of RZV vaccination or preventive care visit for the RZV unvaccinated comparator. Continuous enrollment is determined by Medicare enrollment in the month of the RZV vaccination or preventative care visit and enrollment in at least 11 of the 12 preceding months.

Exclusion criteria:

Beneficiaries who satisfy the following criteria will be excluded:

1. Continuously enrolled only in Medicare Part C in the baseline period, OR
 2. Enrolled in Medicare due to disability as the original qualifying reason for enrollment.
-

Age groups

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Estimated number of subjects

723000

Study design details

Outcomes

The risk of new onset GBS (within 42 days) and Gout (within 30 days) following RZV vaccination using a Self-controlled Risk Interval (SCRI) design and the risk of new onset PMR (within 183 days) and GCA (within 183 days) following RZV vaccination using a cohort design. The risk of new onset SVT within 30 days following RZV vaccination using a SCRI design and the risk of new onset ION within 183 days following RZV vaccination using a cohort design.

Data analysis plan

The analysis plan will include descriptive measures to characterize exposed and unexposed individuals, conditional Poisson regression models for the SCRI, and Cox proportional hazards regression models for the cohort design outcomes. For each outcome there is a primary analysis, secondary analysis and sensitivity analysis. All the statistical analyses will be done in Statistical Analysis System.

9.4. All the statistical tests will be two-sided at alpha level of 0.05. All 95% confidence intervals will be estimated as the point estimate $\pm 1.96 \times \text{standard error}$.

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s), other

CMS Medicare database US United States

Data sources (types)

[Administrative healthcare records \(e.g., claims\)](#)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No